Streetbeat News

Analyst Ratings

EBAY

Mizuho analyst James Lee maintains a Neutral rating on eBay (NASDAQ:EBAY) and raises the price target from $40 to $44.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:13 pm

FOUR

Mizuho analyst Dan Dolev has maintained a Buy rating on Shift4 Payments (NYSE:FOUR) and increased the price target from $82 to $85.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:11 pm

BYND

BMO Capital analyst Andrew Strelzik has maintained a 'Market Perform' rating on Beyond Meat (NASDAQ:BYND) and increased the price target from $7 to $10.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:09 pm

SEE

Mizuho analyst John Roberts has maintained a Neutral rating on Sealed Air (NYSE:SEE) and lowered the price target from $40 to $39.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:09 pm

STAA

Mizuho analyst Anthony Petrone has maintained a Buy rating on Staar Surgical (STAA) but has lowered the price target from $50 to $45.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:07 pm

FLYW

LU

SEZL

Three financial stocks, Flywire Corporation (FLYW), Sezzle Inc. (SEZL), and Lufax Holding Ltd (LU), are considered overbought as of Feb. 28, 2024, based on their RSI values, indicating potential short-term performance concerns. FLYW reported strong Q4 results with significant revenue growth, SEZL also reported positive Q4 results and provided FY24 guidance, and LU received a price target update from Morgan Stanley.

Portfolio Pulse from Avi Kapoor

February 28, 2024 | 2:06 pm

ARVN

BMO Capital analyst Etzer Darout has maintained an Outperform rating on Arvinas (NASDAQ:ARVN) and increased the price target from $89 to $90.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:05 pm

FIS

Mizuho analyst Dan Dolev has maintained a Buy rating on Fidelity National Information Services (FIS) and increased the price target from $73 to $76.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:04 pm

CRDO

Credo Technology Group (NASDAQ:CRDO) has received mixed analyst ratings over the past three months, with a recent trend towards more bullish perspectives. The average 12-month price target for CRDO has been raised to $26.2, indicating a 10.32% increase from the previous target. Analysts from Mizuho, Needham, and Goldman Sachs have adjusted their ratings and price targets, reflecting optimism about CRDO's future performance despite challenges in revenue growth and profitability.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 2:00 pm

VRDN

Viridian Therapeutics (NASDAQ:VRDN) has received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for VRDN has been adjusted to $35.83, down from $37.00, reflecting a 3.16% decrease. The company, a clinical-stage biopharmaceutical firm focusing on thyroid eye disease treatments, faces financial challenges, including a significant revenue decline and below-industry benchmarks in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 2:00 pm